Will Federal Regulators APPROVE The Pfizer Jab?

Nothing says experimental more than a pending FDA approval.

People all over the country are hesitant to get the jab, and everyone who is concerned has every right. After all, these things aren’t even really approved by federal regulators yet….

This could all change in January though.

According to sources, we could see federal regulators approve Pfizer’s Covid-19 vaccine around January of 2022.

This may or may not cure vaccine hesitancy, but at this point people have such little faith in government institutions that an approval will probably have little effect.

If it were to be approved though, would you take the jab?

Take a look:

Ive no clue why it took this long for ⁦@US_FDA⁩ to communicate this information to the public, but this an important step towards transparency. A timeline helps people make decisions and plan.

Pfizer Doesn’t Expect Final Vaccine Approval Until 2022 https://t.co/M73jaopzEU

— Jerome Adams (@JeromeAdamsMD) July 17, 2021

Pfizer and BioNTech have announced that FDA has granted priority review designation to the companies' application for approval of their Covid-19 vaccine. The goal date for a decision from the FDA is January 2022, the companies say. https://t.co/nxKfMmXogU

— CNN (@CNN) July 16, 2021

The Epoch Times presented us with a potential timeframe for the approval:

All three companies have asked for or intend to ask for full approval, which requires more data and a more thorough review.

Dr. Janet Woodcock, the acting commissioner of food and drugs for the FDA, said regulators are targeting January 2022 to be done with the review, but the target “does not mean approval will not happen before that time.”

“Quite to the contrary, the review of this BLA has been ongoing, is among the highest priorities of the agency, and the agency intends to complete the review far in advance” of that target date, she said in a statement.

Pfizer finished submitting the request for approval, formally known as the Biologics License Application (BLA), in May. It includes clinical data from a phase 3 clinical trial that Pfizer and its partner, BioNTech, said showed the jab was 91.3 percent effective against COVID-19 and 100 percent effective against severe disease.

They play a critical, independent role, and today I'm pleased to share that the Agency has accepted our Biologics License Application (BLA) and granted Priority Review designation for our mRNA vaccine to prevent #COVID19 in individuals aged 16+. https://t.co/Zp9llORchz (2/3)

— Albert Bourla (@AlbertBourla) July 16, 2021

JANUARY?! 2022?
What the hell @US_FDA ?
– 3.54 billion vax doses have been admin'ed globally to date
– 300 M doses of Pfizer #COVID19 vaccine
What can possibly explain waiting 6 more months before granting a license for the #vaccine?@EricTopol @gregggonsalves https://t.co/8130O33MNC pic.twitter.com/MN8SW6kKfe

— Laurie Garrett (@Laurie_Garrett) July 16, 2021

Fox Business had more details:

The Advisory Committee on Immunization Practices (ACIP) plans to convene on July 22 to discuss “clinical considerations for additional doses in immunocompromised individuals,” according to a draft agenda posted ahead of the meeting.

The National Institutes of Health defines immunocompromised patients as those with “a reduced ability to fight infections and other diseases,” potentially caused by conditions like “AIDS, cancer, diabetes, malnutrition, and certain genetic disorders” or medicines or treatments like chemotherapy and organ transplants.

Some evidence has indicated immunocompromised individuals, who account for about 2.7% of the country’s population, mount a diminished protective immune response, even after two doses of vaccine. More specifically, one study showed 7-27 days after a second Pfizer dose, there was 75% protection against symptomatic COVID-19 among immunosuppressed patients, compared with 94% overall. The patients also saw less protection against infection at 71% versus 90% overall, after two Pfizer doses.